• 27 April 2016
    • journal article
Abstract
Galectin-3 is a recently developed biomarker of fibrosis, which may play a role in cardiac remodeling and associated with both the progression and severity of heart failure (HF). A prospective cohort study of 190 patients with documented prior myocardial infarction and chronic HF (NYHA class II-IV) was conducted. Patients were divided into 3 groups based on their NYHA functional class. Levels of galectin-3, NT-proBNP, CRP, IL-6, oxidized-LDL, extracellular superoxide dismutase (EC-SOD), 3-nitrotyrosine, SH-groups, cystatin-C were determined. Follow-up period was 26 months, and all-cause mortality was determined as the primary endpoint. Statistical analysis was performed and statistical significance was set at P2800 pg/mL carry a worse prognosis. Galectin-3 level >21 ng/mL associated with increased mortality.